Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in mutant patients with non-small cell lung cancer.

Clinical studies have confirmed epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) used in lung cancer patients with mutations can obtain a better result, but still part of the patients with poor efficacy. mutation is highly related to female, nonsmoking and adenocarcinoma. Thus, we hypothesize that estrogen and circulating HER-2/neu protein might influence the efficacy of EGFR-TKIs in mutant patients with non-small cell lung cancer. HER-2/neu expression level of 357 eligible patients in its peripheral serum was determined using ELISA. The median progression-free survival (PFS) in five groups (premenopausal group, perimenopause group, peri to postmenopausal group, postmenopausal group and control group) was statistically difference ( = 0.025). Premenopausal group could predict the efficacy of EGFR-TKI ( = 2.45, 95% CI = 1.42-4.23, = 0.001). No statistical significance was found in median overall survival (OS) among five groups. Optimal diagnostic cut off value of HER-2/neu was set at 47.5 ng/ml, with = 0.0607. As the cutoff value to 47.5 ng/ml division, concentrations and menopausal status was of no significant difference ( = 0.874). PFS of the group below 47.5 ng/ml was significantly longer than that of the group over 47.5 ng/ml ( = 0.000). HER-2/neu concentration was positively correlated with optimal efficacy ( = 0.042). HER-2/neu concentration over than 47.5 ng/ml was a risk factor of EGFR-TKI prognosis. Premenopausal status is an independent predictor of EGFR-TKI curative effect and circulating HER-2/neu protein is an independent prognostic factor in patients with advanced NSCLC.